Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: A randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial

Journal of Psychopharmacology

Volumn 29, Issue 1, 2015, Pages 69-79

  Laties, Alan M ^a   Flach, Allan J ^b   Baldycheva, Irina ^c   Rak, Ihor ^c   Earley, Willie ^c   Pathak, Sanjeev ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Cataractogenic potential; non inferiority trial; open label; quetiapine; risperidone

Indexed keywords

QUETIAPINE; RISPERIDONE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CATARACT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORTICAL OPACIFICATION; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR OPALESCENCE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTERIOR SUBCAPSULAR OPACIFICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT REFUSAL; ADOLESCENT; CHEMICALLY INDUCED; COMPARATIVE STUDY; MIDDLE AGED; PSYCHOTIC DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CATARACT; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; QUETIAPINE FUMARATE; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84918530422     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114553253     Document Type: Article

References (37)

1. Diagnostic and statistical manual of mental disorders. 1994 ) Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Publishing. Washington, DC: American Psychiatric Publishing ; 1994 :
2. AstraZeneca Pharmaceuticals (2013) Quetiapine fumarate [summary of product characteristics]. Revised. Available at: http://www.medicines.org.uk. Accessed 28March2014.
3. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 ; 154: 672-676
4. Barsa JA, Newton JC, Saunders JC. Lenticular and corneal opacities during phenothiazine therapy. JAMA. 1965 ; 193: 10-12
5. Chylack LT, Leske MC, McCarthy D, Khu P, Kashiwagi T, Sperduto R. Lens opacities classification system II (LOCS II). Arch Ophthalmol. 1989 ; 107: 991-997
6. Chylack LT, Mantell G, Wolfe JK, Friend J, Rosner B. Lovastatin and the human lens; results of a two year study. The MSDRL Study Group. Optom Vis Sci. 1993 ; 70: 937-943
7. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993 ; 29: 321-326
8. Forrest FM, Snow HL, Erickson G, Geiter CW, Laxson GO. Incidence of late "melanosis" side effects in chronic mental patients after long term phenothiazine therapy. Proc West Pharmacol Soc. 1966 ; 9: 18-20
9. Fraunfelder FW. Twice-yearly exams unnecessary for patients taking quetiapine. Am J Ophthalmol. 2004 ; 138: 870-871
10. Friedman JH. Historical perspective on movement disorders. J Clin Psychiatry. 2004 ; 9: 3-8
11. Garner LL, Wang RI, Hieb E. Eye changes following phenothiazine administration. Wis Med J. 1974 ; 73: S119 - S121
12. Greiner AC, Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can Med Assoc J. 1964 ; 90: 663-665
13. Guy W Rockville, MD: US Department of Health, Education, and Welfare ; 1976 :
14. Guy W, Bonato RR 1970 ) CGI clinical global impression. In: GuyWBonatoRR (eds), Manual for the ECDEU assessment battery. 2nd ed revised edn. US Department of Health, Education, and Welfare: Chevy Chase, MD, pp 12-1-12-6. Guy W Bonato RR, ed. Chevy Chase, MD: US Department of Health, Education, and Welfare ; 1970: 12-1-12-6.
15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987 ; 13: 261-276
16. Laties A, Dev V, Geller W. Safety update on lenticular opacities: benign experience with 620,000 US patient exposures to quetiapine. Abstracts of the 39th Annual Meeting of the American College of Neuropsychopharmacology ; 2000 ; 2000..
17. Leske MC, Connell AM, Wu SY, Hyman L, Schachat A. Prevalence of lens opacities in the Barbados Eye Study. Arch Ophthalmol. 1997a ; 115: 105-111
18. Leske MC, Wu SY, Connell AM, Hyman L, Schachat AP. Lens opacities, demographic factors and nutritional supplements in the Barbados Eye Study. Int J Epidemiol. 1997b ; 26: 1314-1322
19. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 ; 353: 1209-1223
20. Magno BV, Datiles MB, Lasa SM. Senile cataract progression studies using the Lens Opacities Classification System II. Invest Ophthalmol Vis Sci. 1993 ; 34: 2138-2141
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 ; 22: 719-748
22. McCarty CA, Wood CA, Fu CL, Livingston PM, Mackersey S, Stanislavsky Y, et al. Schizophrenia, psychotropic medication, and cataract. Ophthalmology. 1999 ; 106: 683-687
23. Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs. 2010 ; 24: 501-526
24. Ruigómez A, Garcia Rodriguez LA, Dev VJ, Arellano F, Raniwala J. Are schizophrenia or antipsychotic drugs a risk factor for cataracts?. Epidemiology. 2000 ; 11: 620-623
25. Sartorius N. Physical illness in people with mental disorders. World Psychiatry. 2007 ; 6: 3-4
26. Satanove A. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA. 1965 ; 191: 263-268
27. Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med. 2001 ; 161: 2021-2026
28. Shahzad S, Suleman MI, Shahab H, Mazour I, Kaur A, Rudzinskiy P, et al. Cataract occurrence with antipsychotic drugs. Psychosomatics. 2002 ; 43: 354-359
29. Siddall JR. The ocular toxic findings with prolonged and high dosage chlorpromazine intake. Arch Ophthalmol. 1965 ; 74: 460-464
30. Siddall JR. Ocular complications related to phenothiazines. Dis Nerv Syst. 1968 ; 29: 10-3
31. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970 ; 212: 11-19
32. Smith D, Pantelis C, McGrath J, Tangas C, Copolov D. Ocular abnormalities in chronic schizophrenia: clinical implications. Aust N Z J Psychiatry. 1997 ; 31: 252-256
33. Souza VB, Moura Filho FJ, Souza FG, Rocha CF, Furtado FA, Goncalves TB, et al. Cataract occurrence in patients treated with antipsychotic drugs. Rev Bras Psiquiatr. 2008 ; 30: 222-226
34. Tan JS, Mitchell P, Rochtchina E, Wang JJ. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. Am J Ophthalmol. 2007 ; 143: 687-689
35. Incidence and progression of cortical, nuclear, and posterior subcapsular cataracts. Am J Ophthalmol. 1994 ; 118: 623-631
36. Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008 ; 7: 58-62
37. Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002 ; 56: 37-46